Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Unresectable Solid Tumor: early-phase trial registry
6 of 7 indexed Unresectable Solid Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 6 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Unresectable Solid Tumor: 7 US clinical trials tracked, 6 recruiting.
Unresectable Solid Tumor is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Relay Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition unresectable-solid-tumor
OPEN 6 | RECR 86% | LATE 0 | EARLY 6 | RANK #2497 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adenovirus (86% recruiting · 7 trials)
Unresectable Solid Tumor lists 6 open slots (86% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Unresectable Solid Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Unresectable Solid Tumor is recruiting above its size-band peers.
6 of 7 indexed trials (85.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Unresectable Solid Tumor research.
Relay Therapeutics accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Unresectable Solid Tumor enrolment sits around 90 participants.
Median target enrolment is 90 among the 7 trials that report a genuine target (sentinel values excluded). 4 of those (57.1%) plan for fewer than 100 participants.
-
Unresectable Solid Tumor research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Relay Therapeutics
NCT05216432
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Frontier Medicines Corporation
NCT06244771
A Beta-only IL-2 ImmunoTherapY Study
Medicenna Therapeutics
NCT05086692
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Clasp Therapeutics
NCT06778863
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Massachusetts General Hospital
NCT06302621
Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy
Washington University School of Medicine
NCT05831579
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
Relay Therapeutics
NCT05759949
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Unresectable Solid Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Unresectable Solid Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Unresectable Solid Tumor page
7 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Unresectable Solid Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Relay Therapeutics sponsors the most Unresectable Solid Tumor trials on record, review their full trial history before evaluating a specific study. See Relay Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Unresectable Solid Tumor condition card totals 7 registered trials; most-linked intervention Fulvestrant; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.